Skip to main content
. 2023 May 9;27:179. doi: 10.1186/s13054-023-04475-w

Table 1.

Clinical, laboratory and EEG variables associated with periodic discharges

Total (n = 92) Periodic discharges p Multivariate analysis
Absent (n = 69) Present (n = 23) p OR IC 95%
Age. years 65 [55.8–73.3] 66 [59–74] 62 [50–73] 0.46
Female 30 (33%) 17 (25%) 13 (57%) 0.005 0.006 4.2 [1.50–11.82]
Sepsis origin
 Abdominal 37 (40%) 30 (43%) 7 (30%) 0.48
 Respiratory 27 (29%) 19 (28%) 8 (35%)
 Urinary 10 (11%) 8 (12%) 2 (9%)
 Soft tissue 9 (10%) 7 (10%) 2 (9%)
 Unknown 5 (5%) 2 (3%) 3 (13%)
 Other 4 (4%) 3 (4%) 1 (4%)
Septic shock 42 (47%) 30 (43%) 12 (53%) 0.47
APACHE II 22 [16–29] 21 [16–26.5] 27 [21–31] 0.049 0.021 1.07 [1.01–1.14]
Non-neuro APACHE II 18 [11–24] 18 [12–23] 19 [12–26] 0.46
CRS-R 18 [2–23] 22 [6–23] 5 [0–7]  < 0.001
Sepsis-associated encephalopathy 66 (72%) 44 (64%) 22 (96%) 0.003
GCS 14 [6–15] 14 [10–15] 7 [3–13]  < 0.001
CAM-ICU+  29/70 (41%) 21/58 (36%) 8/12 (67%) 0.051
RASS < − 3 22 (24%) 11 (16%) 11 (48%) 0.002
Sedation during EEG 30 (33%) 17 (25%) 13 (57%) 0.006
 Propofol dose (mg/kg/day) 20 [14.5–35.5] 15 [4.5–20] 39 [33–53]  < 0.001
 Propofol duration (days) 2 [1–4] 1 [1–2] 5 [3–6.3]  < 0.001
 Mdz dose (mg/kg/day) 0.35 [0.1–0.7] 0.5 [0.2–0.6] 0.3 [0.1–0.7] 0.78
 Mdz duration (days) 2 [1–3] 2 [1.3–2.8] 2 [1–3] 0.96
 Dxd dose (mcg/kg/day) 7.5 [6.3–12.3] 7.1 [5.5–7.5] 25.4 [na] 0.5
 Dxd duration (days) 2 [1.8–2.5] 2 [2–3] 1 [na] 0.35
ICU length stay (days) 3 [2–5] 3 [2–4] 4 [2.5–6] 0.063
Duration of cEEG (h) 70.5 [25–141] 66 [22–96] 128 [93.5–169]  < 0.001
Mechanical ventilation 64 (70%) 44 (64%) 20 (87%) 0.036
Pa/Fio2 227 [162–184] 225 [158–283] 230 [167–301] 0.52
Vasoactive drugs 76 (83%) 55 (80%) 21 (91%) 0.2
Temperature (°C) 37.5 [37.1–38] 37.2 [36.6–37.9] 37.2 [37.1–37.6] 0.15
Laboratory variables
 WBC 18.5 [13.3–26.8] 15 [10.4–23.2] 15.9 [12.3–24.6] 0.62
 Creatinine 1.5 [1.04–3.06] 1.4 [0.96–2.4] 1.76 [1.4–4] 0.15
 Bilirubin 1.05 [0.56–1.7] 0.9 [0.46–1.4] 0.73 [0.5–1.3] 0.16
 NSE 18.8 [13.9–30.5] 16 [13.5–25.3] 21.6 [13.9–30.4] 0.36
 Na+ 137 [135–139] 137 [135–139] 136 [135–138] 0.46
 NH4+ 78 [68–93] 71 [64–121] 85 [68–87] 0.93
 PaCO2 34 [30–38] 34 [30–37] 34 [32–38] 0.62
Acute liver injury 26 (28%) 20 (29%) 6 (26%) 0.79
Acute kidney injury 63 (68%) 47 (68%) 16 (70%) 0.89
Chronic kidney injury 10 (11%) 5 (7%) 5 (22%) 0.053
Antibiotics
 Beta-lactams 78 (85%) 59 (85%) 19 (83%) 0.74
 Cephalosporin 20 (22%) 14 (20%) 6 (26%) 0.56
 Metronidazole 14 (15%) 10 (14%) 4 (17%) 0.74
 Other 35 (38%) 24 (35%) 11 (45%) 0.26

Data are presented as median [interquartile range] or count (percentage)

APACHE-II Acute physiological and chronic health evaluation, CRS-R The Coma Recovery Scale-Revised, Pa/FiO2 Ratio of arterial oxygen partial pressure to fractional inspired oxygen, CAM-ICU The Confusion Assessment Method for the ICU, considered as positive if patients presented with delirium and RASS >  -4, RASS Richmond agitation sedation scale, Mdz Midazolam, Dxd Dexmedetomidine, ICU Intensive care unit, (c)EEG (Continuous) electroencephalogram, T° Body temperature, WBC White blood cells count, NSE Neuron-specific enolase, NH4 Ammonemia in µg/dL, PDs Periodic discharges, RDA Rhythmic delta activity, PDR Posterior dominant rhythm. Mann–Whitney, Fisher’s exact and χ2 tests were used to analyze differences in variables between groups, as appropriate. p < 0.05 was considered statistically significant and marked in bold in the table. For the T° and the other laboratories variables (WBC, creatinine, bilirubin, NSE), the highest value during the ICU period was considered. For the definition of acute/chronic liver/kidney injury, please refer to the text